- Home
- ACHV vs HNNA Comparison
ACHV vs HNNA Comparison
Compare ACHV & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- HNNA
- Stock Information
- Founded
- ACHV N/A
- HNNA 1989
- Country
- ACHV Canada
- HNNA United States
- Employees
- ACHV N/A
- HNNA N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- HNNA Investment Managers
- Sector
- ACHV Health Care
- HNNA Finance
- Exchange
- ACHV Nasdaq
- HNNA Nasdaq
- Market Cap
- ACHV 72.5M
- HNNA 79.4M
- IPO Year
- ACHV N/A
- HNNA N/A
- Fundamental
- Price
- ACHV $3.58
- HNNA $10.91
- Analyst Decision
- ACHV Strong Buy
- HNNA
- Analyst Count
- ACHV 3
- HNNA 0
- Target Price
- ACHV $14.33
- HNNA N/A
- AVG Volume (30 Days)
- ACHV 234.9K
- HNNA 9.4K
- Earning Date
- ACHV 05-13-2025
- HNNA 05-07-2025
- Dividend Yield
- ACHV N/A
- HNNA 5.03%
- EPS Growth
- ACHV N/A
- HNNA 83.55
- EPS
- ACHV N/A
- HNNA 1.25
- Revenue
- ACHV N/A
- HNNA $35,546,000.00
- Revenue This Year
- ACHV N/A
- HNNA N/A
- Revenue Next Year
- ACHV N/A
- HNNA N/A
- P/E Ratio
- ACHV N/A
- HNNA $8.64
- Revenue Growth
- ACHV N/A
- HNNA 41.94
- 52 Week Low
- ACHV $1.84
- HNNA $6.94
- 52 Week High
- ACHV $5.58
- HNNA $13.88
- Technical
- Relative Strength Index (RSI)
- ACHV 69.97
- HNNA 55.42
- Support Level
- ACHV $2.89
- HNNA $10.17
- Resistance Level
- ACHV $3.32
- HNNA $11.10
- Average True Range (ATR)
- ACHV 0.25
- HNNA 0.48
- MACD
- ACHV 0.06
- HNNA 0.00
- Stochastic Oscillator
- ACHV 95.12
- HNNA 71.15
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About HNNA Hennessy Advisors Inc.
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.